



## Review

# Purinergic signalling-evoked intracellular $\text{Ca}^{2+}$ concentration changes in the regulation of chondrogenesis and skeletal muscle formation

Csaba Matta<sup>a,b</sup>, János Fodor<sup>c</sup>, László Csernoch<sup>c</sup>, Róza Zákány<sup>a,\*</sup><sup>a</sup> Department of Anatomy, Histology and Embryology, Faculty of Medicine, University of Debrecen, Debrecen H-4032, Hungary<sup>b</sup> Department of Veterinary Pre-Clinical Sciences, School of Veterinary Medicine and Science, Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7AL, United Kingdom<sup>c</sup> Department of Physiology, Faculty of Medicine, University of Debrecen, Debrecen H-4032, Hungary

## ARTICLE INFO

## Article history:

Received 16 October 2015

Received in revised form

16 December 2015

Accepted 23 January 2016

Available online 16 February 2016

## Keywords:

Cartilage formation

Myogenesis

Mesenchymal stem cells

Purinoreceptor

ATP

Ca-oscillations

## ABSTRACT

It is now widely recognised that changes of the intracellular calcium concentration have deep impact on the differentiation of various non-excitabile cells including the elements of the vertebrate skeleton. It has become evident that purinergic signalling is one of the most ancient cellular mechanisms that can cause such alterations in the intracellular  $\text{Ca}^{2+}$ -homeostasis, which are precisely set either spatially or temporally. Purinergic signalling is believed to regulate intracellular  $\text{Ca}^{2+}$ -concentration of developing cartilage and skeletal muscle cells and suggested to play roles in the modulation of various cellular functions. This idea is supported by the fact that pluripotent mesenchymal cells, chondroprogenitors or muscle precursors, as well as mature chondrocytes all are capable of releasing ectonucleotides, and express various types of purinoreceptors and ectonucleotidases. The presence of the basic components of purinergic signalling proves that cells of the chondrogenic lineage can utilise this mechanism for modulating their intracellular  $\text{Ca}^{2+}$  concentration independently from the surrounding skeletal muscle and bone tissues, which are well known to release ectopurines during development and mechanical stress. In this review, we summarize accumulating experimental evidence supporting the importance of purinergic signalling in the regulation of chondrogenesis and during skeletal muscle formation.

© 2016 Elsevier Ltd. All rights reserved.

## 1. Brief overview of purinergic signalling

Although the physiological role of extracellular purine nucleotides has been implicated early in the 20th century by Drury and Szent-Györgyi [1], it was not until the seminal work of Burnstock et al. on non-adrenergic non-cholinergic transmission in the *taenia coli* [2] that they gained proper acceptance into the

growing community of signalling molecules. Since then purinergic signalling (coined by Burnstock [3]; see also Ref. [4]) has been widely accepted in nearly all eukaryotic organisms [5].


### 1.1. P1 receptors

The evolution of our understanding of purinergic signalling has first led to the separation of the then so-called P1 and P2 receptors based on their sensitivity to adenosine (P1 receptors) and ATP (P2 receptors) [6]. The former are now referred to as adenosine receptors, with four members of the family ( $A_1$ ,  $A_{2A}$ ,  $A_{2B}$ , and  $A_3$ ) [7,8] identified and characterised. All adenosine receptors belong to the large superfamily of G-protein coupled receptors (GPCRs) and affect the intracellular production of cyclic AMP (cAMP) or inositol 1,4,5-trisphosphate ( $\text{IP}_3$ ). Whilst  $A_1$  and  $A_3$  receptors are linked in most cells to  $G_i$  proteins and thus lower cAMP concentration, both  $A_2$  receptors couple to  $G_s$  proteins to increase intracellular cAMP levels [9,10].

**Abbreviations:** AC, adenylate cyclase; ATSC, adipose tissue-derived stem cell; CPC, chondrogenic progenitor cell; DFC, dental follicle cell; ECM, extracellular matrix; ERK, extracellular signal-regulated protein kinase; FGF, fibroblast growth factor; GPCR, G-protein coupled receptor; HDC, high density cultures;  $\text{IP}_3$ , inositol 1,4,5-trisphosphate; MRF, myogenic regulatory factor; MSC, mesenchymal stem cell; MSK, musculoskeletal; NFAT, nuclear factor of activated T lymphocytes; NMDA, N-methyl-D-aspartate type ionotropic glutamate receptor; PI3-K, phosphoinositide 3-kinase; PLC, phospholipase C; PP2B, protein phosphatase 2B (calcineurin); RyR, ryanodine receptor; SERCA, sarcoplasmic/endoplasmic  $\text{Ca}^{2+}$ -ATPase; Shh, sonic hedgehog; SOCE, store operated calcium entry; TGF, transforming growth factor; TRP, transient receptor potential channel.

\* Corresponding author. Fax: +36 52 255 115.

E-mail addresses: [roza@anat.med.unideb.hu](mailto:roza@anat.med.unideb.hu), [matta.csaba@med.unideb.hu](mailto:matta.csaba@med.unideb.hu) (R. Zákány).



**Fig. 1.** Schematic diagram depicting the molecular components of P1 and P2 receptor-mediated signalling in an idealised cell. The downstream effects of P1 adenosine and P2Y purinergic receptor subtypes are determined by the G protein; G<sub>q/11</sub> activates the PLC–IP<sub>3</sub>R pathway, G<sub>s</sub> activates AC and thus elevates cAMP levels, and G<sub>i</sub> inhibits AC activity thus resulting in decreased cAMP levels. Please note that in reality, no cells express all types of P1 and P2 receptors that couple to all intracellular signalling pathways shown at the same time. AC, adenylylase cyclase; PLC, phospholipase C.

## 1.2. P2 receptors

Identification of the members of the P2 receptor family started with the description of their distinct and sometimes contradictory cellular effects [11]. The original notion in 1985 that P2X and P2Y receptors should be distinguished was based on pharmacological data [12]. Today seven members of the ionotropic (P2X<sub>1–7</sub>) and eight members of the metabotropic (P2Y<sub>1,2,4,6,11–14</sub>) purinergic receptors have been cloned and identified in mammals [13,14]. In case of P2X receptors the seven members of the subfamily refer to seven distinct subunits as discussed below. It should be noted that the missing numbers in the P2Y receptor family are for members either present in non-mammalian species (such as P2Y<sub>3</sub>, which was found in birds) [15] or have since been recognized as receptors for other signalling molecules (such as the lysophosphatidylserine receptors P2Y<sub>5</sub> or P2Y<sub>10</sub>) [16,17]. The key components of P1 and P2 receptor-mediated signalling are illustrated in Fig. 1.

### 1.2.1. P2X receptors

P2X receptors form multimeric, both homo- and heteromeric ligand gated channels composed of different members of the subfamily. Typical homomeric channels are the P2X<sub>1</sub> and P2X<sub>7</sub> receptors, while a typical heteromeric receptor is the one composed of P2X<sub>2</sub> and P2X<sub>3</sub> subunits (the P2X<sub>2/3</sub> receptor [18]). Recent data suggest that functional P2X receptors can occur as trimers [19,20]. Nonetheless, all seven P2X receptor subunits share a similar

topology, with two transmembrane domains, an extracellular loop, and the amino and carboxy terminals located intracellularly.

The ion channels formed by P2X receptors are cation selective. Their activation, therefore, results in the depolarization of the cell membrane. In certain cases the depolarization itself, in others the concomitant influx of calcium ions—and the consequent increase in intracellular Ca<sup>2+</sup> concentration ([Ca<sup>2+</sup>]<sub>i</sub>)—is the cellular signal. Ca<sup>2+</sup> ions enter either through the activated P2X receptor or the depolarization of the cell membrane results in the opening of voltage-gated calcium channels. In this respect P2X receptors can either be non-selective channels (such as the P2X<sub>3</sub> receptor), or exhibit a higher permeability for Ca<sup>2+</sup> than for Na<sup>+</sup> (as the P2X<sub>4</sub> receptor where P<sub>Ca</sub>/P<sub>Na</sub> > 4 for the homomeric channel) [21]. The different P2X receptors not only differ in their pharmacology and ion permeation, but also in their gating properties (for excellent recent reviews see Refs. [22,23]).

### 1.2.2. P2Y receptors

P2Y receptors, like adenosine receptors, couple to G-proteins that influence the activity of either phospholipase C (PLC) or adenylylase cyclase (AC) thus influencing the intracellular production of IP<sub>3</sub> or cAMP, respectively. It is important to note that a given P2Y receptor can couple to different G-proteins in different cell types; therefore, it is always necessary to assess the signalling pathways in the cell under investigation. Nevertheless, P2Y<sub>1,2,4,6,11,14</sub> receptors usually activate the IP<sub>3</sub> pathway, while P2Y<sub>12,13</sub> receptors inhibit AC and thus the production of cAMP (for further details see

Ref. [13]). It should be noted that P2Y receptors can also, as described for many GPCRs, couple to ion channels [24].

Not only the signalling pathways but also the pharmacology of the P2Y receptors is quite unique [25–28]. Whilst most P2Y receptors can be activated by ATP (the exception being the P2Y<sub>14</sub> receptor which is activated by UDP-glucose or UDP-galactose); for many ATP is not the primary agonist. P2Y<sub>2,4,6</sub> receptors are considered as pyrimidine receptors as they are more (or at least as in case of P2Y<sub>2</sub>) sensitive to UTP or UDP than to ATP. On the other hand, P2Y<sub>1,12</sub> receptors are sometimes referred to as ADP receptors as ADP is a better agonist (especially for P2Y<sub>12</sub>) than ATP.

### 1.2.3. Expression profile of P2 receptors

The coupling of the P2 receptors to different intracellular signalling pathways in different cell types is already interesting, but the most intriguing feature of these receptors is their expression pattern. Essentially all cells studied so far seem to express a number of different P2 receptors on their surface membrane resulting in a specific expression pattern characteristic to the given cell [29,30]. In certain cases, P2X and P2Y receptors can co-exist and modify the effect of one another. This modification can appear as a synergistic effect on  $[Ca^{2+}]_i$  (for reviews on certain cell types see Refs. [31,32]), or through the intracellular regulation of the receptor [33]. This expression pattern of P2 receptors changes during differentiation, and the pattern seems to be specific for the stage of differentiation. In skeletal muscle, for example, as we described it in a series of papers [34–36], purinergic signalling is present on embryonic and cultured cells, while it is absent on adult muscle fibres. Furthermore, during differentiation in culture, myoblasts responded with small, smaller myotubes with large, while large, multinucleated myotubes again with low level changes in  $[Ca^{2+}]_i$  to purinergic stimulation, reflecting on the probability of a differentiation state-dependent expression pattern of purinoreceptors [37].

## 2. Purinergic signalling in skeletal muscle differentiation

Multi-nucleated mature skeletal muscle fibres generally form through the fusion of myoblasts developed from mesodermal progenitors. During embryogenesis, myoblasts can either proliferate, or differentiate into myotubes. Muscle satellite cells located between the basal lamina and the sarcolemma of muscle fibres represent a committed stem cell population that is responsible for the postnatal growth and regeneration of skeletal muscle. Satellite cells possess multi-lineage differentiation potential, and are thus capable of differentiating into osteocytes, adipocytes or myocytes [38,39]. Skeletal myogenesis depends on the strict regulation of specific gene subsets that control the differentiation of the myogenic progenitors into myofibres. The transcription factors Pax3 and Pax7 play essential roles in the early specification, migration, and myogenic differentiation of satellite cells. Myogenic progenitors expressing Pax3 and Pax7 exhibit increased levels of the myogenic regulatory factors (MRFs) consisting of a group of transcription factors (MyoD, Myf5, myogenin, MRF4) that regulate the skeletal muscle developmental programme. MRF proteins contain a conserved DNA-binding domain that binds the E box sequence CANNTG. Myf5 and MyoD are expressed in proliferating myoblasts and are subject to cell cycle-dependent regulation. Differentiation is then induced upon the activation of myogenin together with MEF2 [40].

Changes in  $[Ca^{2+}]_i$  exert a profound influence on muscle differentiation. The  $Ca^{2+}$ -calmodulin-dependent Ser/Thr phosphoprotein phosphatase calcineurin (protein phosphatase 2B or PP2B) is one of the molecular targets of cytosolic calcium in the regulation of skeletal muscle differentiation [41]. When activated by  $Ca^{2+}$  and calmodulin binding, calcineurin affects

gene expression by dephosphorylating specific substrates, including the four calcineurin-dependent members of the nuclear factor of activated T lymphocytes (NFAT) gene family, NFATc1, NFATc2, NFATc3, and NFATc4. Following dephosphorylation, NFAT translocates from the cytoplasm to the nucleus and activates target genes [42]. Overexpression of the canonical TRPC receptor type 1 (TRPC1) in C2C12 myotubes resulted in altered store operated calcium entry (SOCE), and attenuated differentiation, accompanied by a lower level of nuclear expression of NFAT1 [43]. The neonatal sarcolemmal/endoplasmic  $Ca^{2+}$ -ATPase 1b (SERCA1b) is the major  $Ca^{2+}$  pump in myotubes and young muscle fibres. Interference with SERCA1b mRNA expression results in decreased skeletal muscle differentiation via the regulation of  $[Ca^{2+}]_i$  [44].


### 2.1. P1 adenosine receptor expression and function during skeletal muscle differentiation

Differentiation of skeletal muscle fibres both *in vivo* and *in vitro* is accompanied by the development of voltage-dependent processes and alterations in purinergic signalling. Although the role of adenosine in the regulation of blood supply to skeletal muscle is widely discussed, relatively little is known about the role of P1 adenosine receptors in the function of mature skeletal muscle and in myogenesis. The major source of adenosine formation in skeletal muscle is AMP 5'-nucleotidase, which dephosphorylates AMP. In the muscle interstitium, adenosine has been reported to appear as the result of nucleotide degradation within the skeletal muscle fibres and released to the extracellular space in response to contractions [45]. Adenosine receptor transcripts have been identified in skeletal muscle homogenates decades ago; a high expression level of A<sub>2A</sub> receptor mRNA, moderate signals for A<sub>2B</sub>, and no signals for A<sub>1</sub> and A<sub>3</sub> receptors have been reported [46]. Later, A<sub>2A</sub> and A<sub>2B</sub> receptors were demonstrated in the sarcolemma and cytosol of human skeletal muscle fibres [47]. Skeletal muscle injury elicited a dramatic increase in the expression of A<sub>2B</sub> and A<sub>3</sub>, but not A<sub>1</sub> and A<sub>2A</sub> adenosine receptors [48]. Moreover, a recent publication suggests a role of A<sub>2B</sub> receptor-mediated modulation of the properties of acetylcholine receptors on developing mouse myotubes, resulting in sustained intracellular  $Ca^{2+}$  spikes [49]. Based on these important findings, P1 adenosine receptors may become potential targets for stimulation of skeletal muscle tissue regeneration and functional restoration after injury.

### 2.2. P2 receptor expression and function during skeletal muscle differentiation

The P2 receptor-mediated signal transduction pathway is present on both cultured and freshly isolated embryonic skeletal muscle progenitor cells from mammalian species. P2X<sub>4</sub>, P2X<sub>5</sub>, P2X<sub>7</sub>, P2Y<sub>1</sub> and P2Y<sub>4</sub> receptors have also been demonstrated on multinucleated mouse myoblasts, in addition to P2X<sub>6</sub> receptors that have been described in developing rat skeletal muscle [50]. Metabotropic P2Y receptors could also be detected on developing C2C12 mouse myotubes and on embryonic skeletal muscle; furthermore, P2Y<sub>1</sub>, P2Y<sub>2</sub> and P2Y<sub>4</sub> receptors were also shown to be only temporarily expressed in the embryonic developmental stage and down-regulated in postnatal life [36]. Extracellular ATP can regulate myoblast proliferation and the differentiation of mammalian skeletal muscle [51,52]. During differentiation of C2C12 myoblasts, a continuous increase in their responsiveness to extracellularly applied ATP, as measured by the subsequent change in  $[Ca^{2+}]_i$ , could be detected [37]. When ATP-evoked changes in  $[Ca^{2+}]_i$  were investigated, application of extracellular ATP induced a calcium flux that displayed an early peak and then declined to a steady level. The transient component of calcium flux depended on the activation of P2X receptors and consequent depolarisation, whereas





**Fig. 2.** Mammalian skeletal myogenesis. Myogenic precursor cells (also known as satellite cells in adults) start to proliferate and differentiate into myoblasts. These mononuclear cells proliferate and fuse together (primary fusion step) to give rise to multinucleated myotubes. Additional myoblasts fuse to the existing myotubes in the secondary fusion step to produce even larger myotubes which eventually align to form muscle fibres. This process is mediated by P2X and P2Y receptors. Where data are available, upwards arrows indicate increased activity of downstream pathways following receptor activation. For further details, please see text.

P2Y receptors were found to be responsible for most of the maintained calcium flux. Moreover, the time course of the ATP-evoked flux changed with differentiation [53]. P2Y<sub>1</sub> and P2Y<sub>2</sub> receptors have been identified in human skeletal muscle and ATP evoked an increase in [Ca<sup>2+</sup>]<sub>i</sub> in human myotubes [35,54]. GTP has also been shown to play a role in the early phases of skeletal muscle differentiation [55]. Whilst purinergic receptors clearly play significant roles during the development of skeletal muscle, differentiated muscle fibres barely express them; nonetheless, they reappear after denervation [50].

PKC $\alpha$  overexpression changed the purinergic receptor expression pattern of immature myoblasts and resulted in higher amplitude increases in [Ca<sup>2+</sup>]<sub>i</sub> elicited by ATP, but failed to do so after depolarising stimuli [37]. Whilst nucleotides activate skeletal muscle ryanodine receptors (RyR1), adenosine inhibits the ATP-evoked activation of these receptors. Although ATP reversibly activated RyRs, AMP and adenosine were much weaker agonists [56]. Ca<sup>2+</sup> influx into C2C12 cells via P2X receptors contributes to the phosphorylation of extracellular signal-regulated protein kinase 1/2 (ERK1/2); ATP, ADP, 2MeSADP, UTP and UDP induced a transient increase in the level of p42 and p44 phosphorylation [50,57]. These processes were fully Ca<sup>2+</sup> dependent. On the other hand, ATP activated inositol phosphate formation via a P2Y<sub>1</sub> receptor-dependent manner in primary human skeletal muscle cells. In addition, ATP elicited ERK1/2 phosphorylation in a time and concentration dependent manner, also mainly via P2Y<sub>1</sub> receptors. The ATP mediated ERK1/2 phosphorylation was strictly dependent on PLC and phosphoinositide 3-kinase (PI3-K) activity [58]. The involvement of purinergic receptors in skeletal myogenesis is summarised in Fig. 2.


### 3. Ion channels and Ca<sup>2+</sup> signalling of developing chondrocytes

#### 3.1. Major characteristics of embryonic cartilage formation

Hyaline cartilage plays a very important role during the formation of vertebrate skeletal system as it provides the primitive skeleton of embryos and serves for templates of endochondral bone formation. Cartilage develops from mesenchymal tissue in the

process called chondrogenesis, which is characterised and governed by the expression and activity of the master transcription factor Sox9 [59]. Pluripotent mesenchymal cells proliferate and migrate intensely to form precartilaginous condensations of chondrogenic cells, in which intercellular junctions and local paracrine signalling pathways drive chondroprogenitors towards their final commitment (for reviews see Refs. [60,61]). Initially elongated, the chondroprogenitor cells undergo characteristic morphological changes when they turn into matrix-producing young chondrocytes, obtaining the biomechanically optimal round shape (Fig. 3). Transformation of the macromolecular composition of the extracellular matrix (ECM) and adhesion of the cells to the altered microenvironment have fundamental influence on chondrogenesis [62]. Ultimately, terminal differentiation resulting in hypertrophic chondrocytes, calcification of cartilage ECM, and invasion of blood vessels precedes bone formation. In every step of cartilage formation, many players of the signalling pathways are influenced by local or generalised changes of intracellular Ca<sup>2+</sup> concentration [63].

Permanent hyaline cartilage remains present at certain locations of the skeleton, such as the nasal septum, the wall of airways and the surfaces of bones in synovial joints. Articular cartilage differs from other permanent cartilages by the lack of perichondrium on its surface. This feature is an important factor in the very low regeneration capability of this tissue. Hyaline cartilage is unique among connective tissues in several aspects: it is colonized by a single cell type, the chondrocyte; it does not contain nerves; and healthy cartilage is not penetrated by blood or lymphatic vessels [64]. Mature chondrocytes divide rarely if at all and live in a unique niche in a specialised ECM, which is the product of these cells. A typical location of this tissue in the skeletal system is the surface of bones in synovial joints, where complex load, deformation, and fluid shear are exerted on articular cartilage during locomotion and other physical activities. Chondrocytes are also challenged by osmotic and hypoxic stress under physiological circumstances [65]. Whilst optimal mechanical stimulation is necessary for cartilage development [66] and homeostasis, extreme levels of loading have also been shown to initiate cartilage degradation [65]. A recent publication reported that *in ovo* immobilization of chicken embryos resulted in fused articular surfaces in the knee joint



**Fig. 3.** The main steps of chondrogenesis. Undifferentiated mesenchymal stem cells (MSCs) are recruited to the sites of cartilage formation. Following migration and local proliferation cell density increases (condensation), which triggers a set of intracellular events culminating in overt chondrogenesis accompanied by a change in morphology (acquire the characteristic ovoid shape) and start to deposit cartilage ECM molecules. Amongst other factors, the process is regulated by the master chondrogenic transcription factor Sox9, which is responsible for the expression of ECM components. The precisely set Ca<sup>2+</sup> homeostasis and the tight regulation of other ionic currents through components of the channelome of differentiating and mature chondrocytes are essential in mediating the effects of external cues of the chondrocyte niche such as the mechanical or osmotic environment. Various protein kinases/phosphoprotein phosphatases also play essential roles in the control of chondrogenesis. The involvement of P1 adenosine receptors, as well as P2X and P2Y purinergic receptors in modulating the main steps of chondrogenesis is shown in boxes below the schematic diagrams. Where data are available, arrows indicate increased (upwards arrow) or decreased (downwards arrow) activity of downstream pathways following receptor activation. See further explanation in text.

[67]. Albeit chondrocytes are generally considered as non-excitable cells the above findings all suggest that either mature or differentiating chondrocytes are able to “sense” various environmental stimuli and transmit those into the cells, where signal transduction pathways influencing metabolism, transcriptional activity, differentiation programmes or proliferation of cartilage cells can be altered.

### 3.2. Ion channels and intracellular Ca<sup>2+</sup>-concentration changes in chondrogenic cells

Plasma membrane ion channels are the primary candidates to link these extracellular stimuli to the internal milieu of either developing or mature chondrocytes. Indeed, various plasma membrane receptors which are sensitive to mechanical load, fluid shear or osmotic changes, are present and function on mature chondrocytes

(for a review, see Ref. [68]). Some of them, such as several members of the transient receptor potential (TRP) channel family [69], purinoreceptors [70], or the *N*-methyl-*D*-aspartate type ionotropic glutamate receptor (NMDAR) [71] are known to function as cation channels with considerable permeability for Ca<sup>2+</sup> and are involved in the Ca<sup>2+</sup> homeostasis of pluripotent mesenchymal stem cells (MSCs) (for a recent review, see Ref. [63]).

Cartilage formation requires a concerted action of numerous intracellular signal transduction molecules [60], many of which are sensitive to the changes of intracellular Ca<sup>2+</sup> concentration. Our previous findings indicated that inhibition of calcineurin by cyclosporine A seriously impaired *in vitro* chondrogenesis in chicken limb-bud derived high density cultures (HDC) [72]. We also detected precisely set changes in basal cytosolic Ca<sup>2+</sup> concentration during chondrogenesis when a day-by-day variation of this cellular parameter was detected by single cell fluorescent Ca<sup>2+</sup> imaging

[73]. A characteristic peak in cytosolic free  $\text{Ca}^{2+}$  concentration was found on day 3 of culturing (approximately 140 nM, as compared to 100 nM prior to or after this day). Of note, this is the period of the culturing when the majority of the chondrogenic cells differentiate to matrix producing chondroblasts in this model. This peak in cytosolic  $\text{Ca}^{2+}$  concentration was found to be indispensable to proper differentiation of cells in HDC because chelation of extracellular  $\text{Ca}^{2+}$  on culturing days 2 or 3 resulted in significantly lower cytosolic  $\text{Ca}^{2+}$  concentration and impaired chondrogenesis, demonstrated by an almost completely abolished cartilage matrix production. In these experiments, proliferation of the differentiating chondrogenic cells was extremely dependent on a well-defined range of cytosolic  $\text{Ca}^{2+}$  concentration [73]. In further experiments, we have proved the dependence of the above changes in cytosolic  $\text{Ca}^{2+}$  concentration on purinergic signalling via ionotropic  $\text{P2X}_4$  receptors [74]. Besides the long term day-by-day changes of the cytosolic  $\text{Ca}^{2+}$  concentration, we have also detected rapid  $\text{Ca}^{2+}$  oscillations in the differentiating chondrocytes. The periodicity of these oscillations was approximately 4–5 transients/minute and the oscillations in chondrifying mesenchymal cells were found to be mainly dependent on the availability of extracellular  $\text{Ca}^{2+}$  as removal of free  $\text{Ca}^{2+}$  from the bath solution immediately abolished these oscillations in most of the cells examined. However, store-operated calcium entry (SOCE) was also found to be essential for the maintenance of the  $\text{Ca}^{2+}$  oscillations [75]. We demonstrated that a developmental switch in the expression and function of voltage-gated potassium channels [76] and activity of voltage dependent  $\text{Ca}^{2+}$  channels [75,77] influenced  $\text{Ca}^{2+}$  oscillations in chondrogenic cells.

The significance of  $\text{Ca}^{2+}$  signalling in chondrogenesis can be underlined by the fact that Sox9, the master transcription factor of chondrogenesis and key element of sex determination, can be translocated to the nucleus either by calmodulin in a  $\text{Ca}^{2+}$ -dependent fashion or by importin- $\beta$  in a  $\text{Ca}^{2+}$ -independent mechanism. Impairment of the calmodulin-driven nuclear shuttle of Sox9 causes campomelic dysplasia/sex reversal, a severe human syndrome affecting skeletogenesis and sexual differentiation [78].

Considering the above, the importance of the changes of intracellular  $\text{Ca}^{2+}$  concentration during differentiation of chondrocytes, as well as in maintenance of the healthy mature cartilage seems to be unquestionable. In the following sections of this review article, we focus on the current knowledge on the significance of purinergic signalling in the regulation of the differentiation and  $\text{Ca}^{2+}$  homeostasis of chondrocytes.

#### 4. Purinergic signalling during chondrogenesis

Mature articular chondrocytes have been shown to express various P1 and P2 purinergic receptors including  $\text{A}_1$ ,  $\text{A}_{2\text{A}}$  and  $\text{A}_{2\text{B}}$ , as well as different subtypes of  $\text{P2X}$  ( $\text{P2X}_{1,2,3,4,7}$ ) and  $\text{P2Y}$  ( $\text{P2Y}_{1,2,4,6}$ ) receptors [79,80]. Given that P1 and P2 receptors are important regulators of mechanosensation or mechanotransduction in mature chondrocytes [79], it is plausible to assume that they may also be involved in the regulation of chondrogenesis.

The role of purinergic signalling has been widely studied in the differentiation of many cell types (for a review, see Ref. [81]). Since the development of cartilage (and to a limited extent its repair) is dependent on the differentiation of chondroblasts and chondrocytes from chondroprogenitor MSCs [82], we will focus on the chondrogenic differentiation of these cells in the context of purinergic signalling. Despite the limited number of studies in this field, accumulating evidence supports the importance of extracellular nucleotides in the regulation of maintenance, proliferation and differentiation of MSCs.

##### 4.1. P1 adenosine receptor expression and function during chondrogenesis

As it could be expected from a cell type with a broad, multilineage differentiation potential, MSCs were found to express  $\text{A}_{1,2\text{A},2\text{B}}$  and  $\text{A}_3$  receptor subtypes of the P1 adenosine receptor family; activation of  $\text{A}_1$  and  $\text{A}_{2\text{A}}$  receptors has been shown to increase proliferation, whilst the most abundant  $\text{A}_{2\text{B}}$  receptors mediate osteogenic differentiation of primary human bone marrow stromal cells [83]. In a different study, stimulation of the  $\text{A}_1$  receptor was demonstrated to enhance osteogenic differentiation of human dental pulp-derived MSCs [84]. Interestingly, no data are available as to whether P1 adenosine receptors are *de facto* involved in the regulation of chondrogenesis. In a migratory cell population derived from human osteoarthritic knee articular cartilage with a strong chondrogenic differentiation potential termed CPCs [85], we have recently established the P1 purinergic receptor profile, which correlated well with that of MSCs as CPCs expressed  $\text{A}_1$ ,  $\text{A}_{2\text{A}}$ , and  $\text{A}_{2\text{B}}$ , but no  $\text{A}_3$  receptors [86]. It should be noted that the same P1 receptor subtypes were found to be expressed in articular chondrocytes [87].  $\text{A}_{2\text{A}}$  and  $\text{A}_{2\text{B}}$  adenosine receptors are of particular importance as these are coupled to  $\text{G}_\text{s}$ , which stimulates AC and produces a cAMP signal [88]; cAMP mediated signalling is a well known mediator of chondrogenesis as well as in maintaining the chondrocyte phenotype [89].

##### 4.2. P2 purinergic receptor expression and function during chondrogenesis

Compared to P1 receptors, more data supporting the role of P2 receptors in chondrogenesis is available. However, there are some controversies as to whether purinergic signalling is a positive or negative regulator of chondrogenesis; some reports suggest that extracellular nucleotides negatively regulate cartilage metabolism whilst others describe beneficial effects of ATP.

The P2 receptor profiling of human MSCs derived from various sources have only recently been performed. Adipose tissue-derived stem cells (ATSCs) and dental follicle cells (DFCs) derived from the ectomesenchyme expressed some  $\text{P2X}$  ( $\text{P2X}_{3,4,5,6,7}$ ) and all 8  $\text{P2Y}$  receptor subtypes; interestingly, no mRNA transcripts of  $\text{P2X}_1$  and  $\text{P2X}_2$  receptors were identified in either cell type [90,91]. Extracellular nucleotides acting through P2 receptors (primarily  $\text{P2X}_6$ ,  $\text{P2Y}_4$ ,  $\text{P2Y}_6$ ,  $\text{P2Y}_{13}$  and  $\text{P2Y}_{14}$ ) are important modulators of MSC differentiation towards the osteogenic and adipogenic lineages [90–92]. The purinergic concept of MSC differentiation is further supported by a recent study showing substantial changes in ectonucleotide metabolism and ecto-nucleotidase expression profiles following chondrogenic differentiation of human umbilical cord-derived MSCs [93].

The specific mechanism as to how P2 receptors mediate these events remains elusive.  $\text{Ca}^{2+}$  signalling is a major regulator of differentiation [63] and nucleotides acting through P2 receptors can either elicit  $\text{Ca}^{2+}$  influx or mobilise  $\text{Ca}^{2+}$  from intracellular stores. The  $\text{Ca}^{2+}$  homeostasis of MSCs has been mapped earlier and  $\text{Ca}^{2+}$  oscillations have been reported to be driven by an autocrine/paracrine purinergic loop, whereby ATP released through hemi-gap junctions triggered  $\text{P2Y}_1$  metabotropic purinergic receptors and  $\text{Ca}^{2+}$  release via  $\text{PLC-}\beta$  and  $\text{IP}_3\text{R}$  signalling [94]. In migratory CPCs, we have recently confirmed the mRNA and protein level expression of certain  $\text{P2X}$  ( $\text{P2X}_{1,4,5,6,7}$ , but not  $\text{P2X}_2$  and  $\text{P2X}_3$ ) and all  $\text{P2Y}$  receptors [86]. Our results suggest the functionality of  $\text{P2Y}_1$ ,  $\text{P2Y}_2$ ,  $\text{P2Y}_4$ , as well as  $\text{P2X}_4$  and  $\text{P2X}_6$  receptor subtypes in CPCs, which shows a very good correlation with previous data implicating the P2 receptor subtypes  $\text{P2X}_6$ ,  $\text{P2Y}_4$  and  $\text{P2Y}_{14}$  to be key regulators in MSC commitment [91]. Given the multilineage differentiation capacity of CPCs to the osteogenic, adipogenic

and chondrogenic lineages, their P1 and P2 receptor profiles are in good correlation with the above data. Further experiments need to confirm the specific role of these receptors in lineage-specific differentiation.

Whilst signalling through P2 receptors seems to promote differentiation of MSCs, their role in chondrogenic micromass cultures is less straightforward. The first study on the involvement of purinergic signalling in chondrogenesis *in vitro* showed that ATP acting on the P2Y<sub>1</sub> receptor inhibited cartilage formation in HDCs of embryonic chick limb bud-derived mesenchymal cells [95]. In contrast, our group has reported that cells in HDC responded to extracellular ATP by elevating their intracellular Ca<sup>2+</sup> levels mainly at the time of chondroblast formation and administration of ATP to the culture medium stimulated chondrogenesis [74]. Whilst Western blot analyses revealed the presence of many purinoreceptors, i.e. P2X<sub>1,4,5</sub> and P2X<sub>7</sub> of the P2X-family and P2Y<sub>1,2,3,4</sub> and P2Y<sub>5</sub> of P2Y receptors in cells of differentiating micromass cultures, the receptor primarily responsible for the rise of Ca<sup>2+</sup> concentration evoked by extracellular ATP seemed to be P2X<sub>4</sub> receptor [74]. Earlier we reported that this receptor contributed to the elevation of cytosolic Ca<sup>2+</sup> levels of chondrogenic cells on day 3 of culturing [73]. The apparent discrepancy between these studies may be explained by the fact that whilst Meyer et al. used cultures established from mesenchymal cells derived from the forelimbs only [95], the micromass cultures used in our study were of mixed origin containing progenitor cells from both fore and hind limb buds [74]. It has long been known that chondrogenesis in HDC derived from wing and leg precartilaginous cells is affected differently by certain morphogens such as transforming growth factor-β1 (TGF-β1) or retinoic acid, and they also differ from each other in condensation morphology and organisation of fibronectin during the early phase of differentiation [96]. The discrepancy may also indicate that ATP, acting through different purinergic receptor subclasses, is able to precisely, albeit sometimes contrarily, regulate chondrogenesis.

Another study has also shown that intracellular oscillations in ATP, acting via P2X<sub>4</sub> receptors, have an essential role in pre-chondrogenic condensation [97] and mediate the inductive action of fibroblast growth factor (FGF) and sonic hedgehog (Shh), proposing the hypothesis that morphogens organise skeletal patterns via ATP oscillations [98]. Purinergic signalling was reported playing role in foetal articular cartilage repair in rat embryos *in vivo*. Although the authors did not identify the specific receptor involved in the process, they showed the presence of a signalling pathway that used the intercellular transfer of ATP and increased cytosolic Ca<sup>2+</sup> levels, and expression of *c-fos* in foetal articular cartilage [99]. The involvement of P1 and P2 receptors in chondrogenesis is summarised in Fig. 3.

## 5. Concluding remarks

It is clear that precisely set intracellular Ca<sup>2+</sup>-concentration changes exhibited by developing chondrocytes and skeletal muscle fibres play essential roles at every step of their differentiation. Purinergic signalling is one of the most ancient mediators of cell-to-cell communication and can modulate the pattern of the intracellular Ca<sup>2+</sup>-concentration changes. Bone, skeletal muscle and cartilage abundantly express various purinergic receptors and accumulating evidence support that extracellular purines participate in the regulation of the proliferation, differentiation and mechanosensation of skeletal tissues. Developing chondrocytes and skeletal muscle fibres express various types of purinoreceptors, offering the ability of their responsiveness to ectopurines and experiments prove that both tissues contain resident cells secreting various purinergic ligands.

On the basis of these experimental data, one can propose that it would be plausible to utilize ectopurines to facilitate tissue regeneration of damaged cartilage or skeletal muscle. Nonetheless, the ubiquitous nature of signalling mediated by ectopurines, that is, its presence and operation in virtually all tissues and cells, has to be considered if any *in vivo* therapeutic intervention is designed to target this mechanism.

## Contributors

The authors researched, discussed and approved the concept, drafted and submitted the commissioned paper. All co-authors made a significant intellectual contribution to the concept of the manuscript.

## Conflict of interest

The authors wrote this paper within the scope of their academic and affiliated research positions. The authors do not have any commercial relationships that could be construed as biased or inappropriate. There are no competing interests.

## Acknowledgements

C.M. is supported by the European Union through a Marie Curie Intra-European Fellowship for career development (project number 625746; acronym: CHONDRION; FP7-PEOPLE-2013-IEF). Part of the work reviewed here from the laboratory of R.Z. was supported by the Hungarian Government and the European Union (grant number GOP-1.1.1-11-2012-0197). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

## References

- [1] A.N. Drury, A. Szent-Gyorgyi, The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart, *J. Physiol.* 68 (1929) 213–237.
- [2] G. Burnstock, G. Campbell, M. Bennett, M.E. Holman, Inhibition of the smooth muscle on the taenia coli, *Nature* 200 (1963) 581–582.
- [3] G. Burnstock, Neural nomenclature, *Nature* 229 (1971) 282–283.
- [4] G. Burnstock, Purinergic nerves, *Pharmacol. Rev.* 24 (1972) 509–581.
- [5] S.J. Fountain, Primitive ATP-activated P2X receptors: discovery, function and pharmacology, *Front. Cell. Neurosci.* 7 (2013) 247.
- [6] G. Burnstock, A basis for distinguishing two types of purinergic receptors, in: R. Straub, L. Boris (Eds.), *Cell Membrane Receptors for Drugs and Hormones: A Multidisciplinary Approach*, Raven Press, New York, 1978, pp. 107–118.
- [7] B.B. Fredholm, A.P. Ijzerman, K.A. Jacobson, K.N. Klotz, J. Linden, International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors, *Pharmacol. Rev.* 53 (2001) 527–552.
- [8] B.B. Fredholm, A.P. Ijzerman, K.A. Jacobson, J. Linden, C.E. Muller, International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors—an update, *Pharmacol. Rev.* 63 (2011) 1–34.
- [9] M. Klinger, M. Freissmuth, C. Nanoff, Adenosine receptors: G protein-mediated signalling and the role of accessory proteins, *Cell. Signal.* 14 (2002) 99–108.
- [10] K.N. Klotz, Adenosine receptors and their ligands, *Naunyn-Schmiedeberg Arch. Pharmacol.* 362 (2000) 382–391.
- [11] S.E. O'Connor, I.A. Dainty, P. Leff, Further subclassification of ATP receptors based on agonist studies, *Trends Pharmacol. Sci.* 12 (1991) 137–141.
- [12] G. Burnstock, C. Kennedy, Is there a basis for distinguishing two types of P2-purinoreceptor? *Gen. Pharmacol.* 16 (1985) 433–440.
- [13] M.P. Abbracchio, G. Burnstock, J.M. Boeynaems, E.A. Barnard, J.L. Boyer, C. Kennedy, G.E. Knight, M. Fumagalli, C. Gachet, K.A. Jacobson, G.A. Weisman, International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy, *Pharmacol. Rev.* 58 (2006) 281–341.
- [14] R.A. North, Molecular physiology of P2X receptors, *Physiol. Rev.* 82 (2002) 1013–1067.
- [15] Q. Li, M. Olesky, R.K. Palmer, T.K. Harden, R.A. Nicholas, Evidence that the p2y3 receptor is the avian homologue of the mammalian P2Y6 receptor, *Mol. Pharmacol.* 54 (1998) 541–546.
- [16] A.P. Davenport, S.P. Alexander, J.L. Sharman, A.J. Pawson, H.E. Benson, A.E. Monaghan, W.C. Liew, C.P. Mpamhanga, T.I. Bonner, R.R. Neubig, J.P. Pin, M.

- Spedding, A.J. Harmar, International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands, *Pharmacol. Rev.* 65 (2013) 967–986.
- [17] M. Ikubo, A. Inoue, S. Nakamura, S. Jung, M. Sayama, Y. Otani, A. Uwamizu, K. Suzuki, T. Kishi, A. Shuto, J. Ishiguro, M. Okudaira, K. Kano, K. Makide, J. Aoki, T. Ohwada, Structure-activity relationships of lysophosphatidylserine analogs as agonists of G-protein-coupled receptors GPR34, P2Y10, and GPR174, *J. Med. Chem.* 58 (2015) 4204–4219.
- [18] G.E. Torres, T.M. Egan, M.M. Voigt, Hetero-oligomeric assembly of P2X receptor subunits. Specificities exist with regard to possible partners, *J. Biol. Chem.* 274 (1999) 6653–6659.
- [19] K. Kaczmarek-Hajek, E. Lorinczi, R. Hausmann, A. Nicke, Molecular and functional properties of P2X receptors—recent progress and persisting challenges, *Purinergic Signal.* 8 (2012) 375–417.
- [20] A. Nicke, H.G. Baumert, J. Rettinger, A. Eichele, G. Lambrecht, E. Mutschler, G. Schmalzing, P2X1 and P2X3 receptors form stable trimers: a novel structural motif of ligand-gated ion channels, *EMBO J.* 17 (1998) 3016–3028.
- [21] M. Garcia-Guzman, F. Soto, J.M. Gomez-Hernandez, P.E. Lund, W. Stuhmer, Characterization of recombinant human P2X4 receptor reveals pharmacological differences to the rat homologue, *Mol. Pharmacol.* 51 (1997) 109–118.
- [22] C. Habermacher, K. Dunning, T. Chataigneau, T. Grutter, Molecular structure and function of P2X receptors, *Neuropharmacology* (2015).
- [23] D.S. Samways, Z. Li, T.M. Egan, Principles and properties of ion flow in P2X receptors, *Front. Cell. Neurosci.* 8 (2014) 6.
- [24] A.K. Filippov, J.M. Fernandez-Fernandez, S.J. Marsh, J. Simon, E.A. Barnard, D.A. Brown, Activation and inhibition of neuronal G protein-gated inwardly rectifying K(+) channels by P2Y nucleotide receptors, *Mol. Pharmacol.* 66 (2004) 468–477.
- [25] A. Brunschweiger, C.E. Muller, P2 receptors activated by uracil nucleotides—an update, *Curr. Med. Chem.* 13 (2006) 289–312.
- [26] C.E. Muller, P2-pyrimidineric receptors and their ligands, *Current Pharm. Des.* 8 (2002) 2353–2369.
- [27] R.F. Storey, Biology and pharmacology of the platelet P2Y12 receptor, *Current Pharm. Des.* 12 (2006) 1255–1259.
- [28] I. von Kugelgen, A. Wetter, Molecular pharmacology of P2Y-receptors, *Naunyn-Schmiedeberg's Arch. Pharmacol.* 362 (2000) 310–323.
- [29] E. Bulanova, S. Bulfone-Paus, P2 receptor-mediated signaling in mast cell biology, *Purinergic Signal.* 6 (2010) 3–17.
- [30] L.Y. Lenertz, C.J. Baughman, N.V. Waldschmidt, R. Thaler, A.J. van Wijnen, Control of bone development by P2X and P2Y receptors expressed in mesenchymal and hematopoietic cells, *Gene* 570 (2015) 1–7.
- [31] P. Petit, A.D. Lajoix, R. Gross, P2 purinergic signalling in the pancreatic beta-cell: control of insulin secretion and pharmacology, *Eur. J. Pharm. Sci.* 37 (2009) 67–75.
- [32] S.S. Stojilkovic, M.L. He, T.A. Koshimizu, A. Balik, H. Zemkova, Signaling by purinergic receptors and channels in the pituitary gland, *Mol. Cell. Endocrinol.* 314 (2010) 184–191.
- [33] D. Becker, R. Woltersdorf, W. Boldt, S. Schmitz, U. Braam, G. Schmalzing, F. Markwardt, The P2X7 carboxyl tail is a regulatory module of P2X7 receptor channel activity, *Journal Biol. Chem.* 283 (2008) 25725–25734.
- [34] C. Collet, C. Strube, L. Csernoch, N. Mallouk, C. Ojeda, B. Allard, V. Jacquemond, Effects of extracellular ATP on freshly isolated mouse skeletal muscle cells during pre-natal and post-natal development, *Pflugers Arch.* 443 (2002) 771–778.
- [35] J. Cseri, H. Szappanos, G.P. Szigeti, Z. Csernatony, L. Kovacs, L. Csernoch, A purinergic signal transduction pathway in mammalian skeletal muscle cells in culture, *Pflugers Arch.* 443 (2002) 731–738.
- [36] T. Deli, H. Szappanos, G.P. Szigeti, J. Cseri, L. Kovacs, L. Csernoch, Contribution from P2X and P2Y purinoreceptors to ATP-evoked changes in intracellular calcium concentration on cultured myotubes, *Pflugers Arch.* 453 (2007) 519–529.
- [37] T. Deli, B.I. Toth, G. Czifra, H. Szappanos, T. Biro, L. Csernoch, Differences in purinergic and voltage-dependent signalling during protein kinase Calpha overexpression- and culturing-induced differentiation of C2C12 myoblasts, *J. Muscle Res. Cell Motil.* 27 (2006) 617–630.
- [38] A. Asakura, M. Komaki, M. Rudnicki, Muscle satellite cells are multipotential stem cells that exhibit myogenic, osteogenic, and adipogenic differentiation, *Differentiation* 68 (2001) 245–253.
- [39] B. Peault, M. Rudnicki, Y. Torrente, G. Cossu, J.P. Tremblay, T. Partridge, E. Gussoni, L.M. Kunkel, J. Huard, Stem and progenitor cells in skeletal muscle development, maintenance, and therapy, *Mol. Ther.* 15 (2007) 867–877.
- [40] N.A. Dumont, Y.X. Wang, M.A. Rudnicki, Intrinsic and extrinsic mechanisms regulating satellite cell function, *Development* 142 (2015) 1572–1581.
- [41] B.B. Friday, V. Horsley, G.K. Pavlath, Calcineurin activity is required for the initiation of skeletal muscle differentiation, *J. Cell Biol.* 149 (2000) 657–666.
- [42] K. Sakuma, A. Yamaguchi, The functional role of calcineurin in hypertrophy, regeneration, and disorders of skeletal muscle, *J. Biomed. Biotechnol.* 2010 (2010) 721219.
- [43] T. Olah, J. Fodor, O. Ruzsnavszky, J. Vincze, C. Berbey, B. Allard, L. Csernoch, Overexpression of transient receptor potential canonical type 1 (TRPC1) alters both store operated calcium entry and depolarization-evoked calcium signals in C2C12 cells, *Cell Calcium* 49 (2011) 415–425.
- [44] A. Toth, J. Fodor, J. Vincze, T. Olah, T. Juhasz, R. Zakany, L. Csernoch, E. Zador, The Effect of SERCA1b silencing on the differentiation and calcium homeostasis of C2C12 skeletal muscle cells, *PLoS One* 10 (2015) e0123583.
- [45] F.I. Achike, H.J. Ballard, Influence of stimulation parameters on the release of adenosine, lactate and CO2 from contracting dog gracilis muscle, *J. Physiol.* 463 (1993) 107–121.
- [46] A.K. Dixon, A.K. Gubitz, D.J. Sirinathsinghji, P.J. Richardson, T.C. Freeman, Tissue distribution of adenosine receptor mRNAs in the rat, *Br. J. Pharmacol.* 118 (1996) 1461–1468.
- [47] J. Lynge, Y. Hellsten, Distribution of adenosine A1, A2A and A2B receptors in human skeletal muscle, *Acta Physiol. Scand.* 169 (2000) 283–290.
- [48] G.L. Warren, T. Hulderman, A. Liston, P.P. Simeonova, Toll-like and adenosine receptor expression in injured skeletal muscle, *Muscle Nerve* 44 (2011) 85–92.
- [49] A. Bernareggi, E. Luin, B. Pavan, G. Parato, M. Sciancalepore, R. Urbani, P. Lorenzon, Adenosine enhances acetylcholine receptor channel openings and intracellular calcium 'spiking' in mouse skeletal myotubes, *Acta Physiol.* 214 (2015) 467–480.
- [50] G. Burnstock, T.R. Arnett, I.R. Orriss, Purinergic signalling in the musculoskeletal system, *Purinergic Signal.* 9 (2013) 541–572.
- [51] T. Martinello, M.C. Baldoiu, L. Morbiato, M. Paganin, E. Tarricone, G. Schiavo, E. Bianchini, D. Sandona, R. Betto, Extracellular ATP signaling during differentiation of C2C12 skeletal muscle cells: role in proliferation, *Mol. Cell. Biochem.* 351 (2011) 183–196.
- [52] I.R. Orriss, The role of purinergic signalling in the musculoskeletal system, *Auton. Neurosci.* 191 (2015) 124–134.
- [53] G.P. Szigeti, H. Szappanos, T. Deli, J. Cseri, L. Kovacs, L. Csernoch, Differentiation-dependent alterations in the extracellular ATP-evoked calcium fluxes of cultured skeletal muscle cells from mice, *Pflugers Arch.* 453 (2007) 509–518.
- [54] C.E. Parr, D.M. Sullivan, A.M. Paradiso, E.R. Lazarowski, L.H. Burch, J.C. Olsen, L. Erb, G.A. Weisman, R.C. Boucher, J.T. Turner, Cloning and expression of a human P2U nucleotide receptor, a target for cystic fibrosis pharmacotherapy, *Proc. Natl. Acad. Sci. U. S. A.* 91 (1994) 13067.
- [55] T. Pietrangelo, B. Fioretti, R. Mancinelli, L. Catacuzzeno, F. Franciolini, G. Fano, S. Fulle, Extracellular guanosine-5'-triphosphate modulates myogenesis via intermediate Ca(2+)-activated K+ currents in C2C12 mouse cells, *J. Physiol.* 572 (2006) 721–733.
- [56] D.R. Laver, G.K. Lenz, G.D. Lamb, Regulation of the calcium release channel from rabbit skeletal muscle by the nucleotides ATP, AMP IMP and adenosine, *J. Physiol.* 537 (2001) 763–778.
- [57] W. Banachewicz, D. Suplat, P. Krzeminski, P. Pomorski, J. Baranska, P2 nucleotide receptors on C2C12 satellite cells, *Purinergic Signal.* 1 (2005) 249–257.
- [58] C. May, L. Weigl, A. Karel, M. Hohenegger, Extracellular ATP activates ERK1/ERK2 via a metabotropic P2Y1 receptor in a Ca2+ independent manner in differentiated human skeletal muscle cells, *Biochem. Pharmacol.* 71 (2006) 1497–1509.
- [59] V. Lefebvre, B. de Crombrugge, Toward understanding SOX9 function in chondrocyte differentiation, *Matrix Biol.* 16 (1998) 529–540.
- [60] R. Cancedda, P. Castagnola, F.D. Cancedda, B. Dozin, R. Quarto, Developmental control of chondrogenesis and osteogenesis, *Int. J. Dev. Biol.* 44 (2000) 707–714.
- [61] G. Karsenty, H.M. Kronenberg, C. Settembre, Genetic control of bone formation, *Annu. Rev. Cell Dev. Biol.* 25 (2009) 629–648.
- [62] D. Docheva, C. Popov, P. Alberton, A. Aszodi, Integrin signaling in skeletal development and function, *Birth Defects Res. C Embryo Today* 102 (2014) 13–36.
- [63] C. Matta, R. Zakany, Calcium signalling in chondrogenesis: implications for cartilage repair, *Front. Biosci.* 5 (2013) 305–324.
- [64] D. Pfander, K. Gelse, Hypoxia and osteoarthritis: how chondrocytes survive hypoxic environments, *Current Opin. Rheumatol.* 19 (2007) 457–462.
- [65] D.J. Leong, J.A. Hardin, N.J. Cobelli, H.B. Sun, Mechanotransduction and cartilage integrity, *Ann. N. Y. Acad. Sci.* 1240 (2011) 32–37.
- [66] N.C. Nowlan, J. Sharpe, K.A. Roddy, P.J. Prendergast, P. Murphy, Mechanobiology of embryonic skeletal development: insights from animal models, *Birth Defects Res. C Embryo Today* 90 (2010) 203–213.
- [67] K.A. Roddy, P.J. Prendergast, P. Murphy, Mechanical influences on morphogenesis of the knee joint revealed through morphological, molecular and computational analysis of immobilised embryos, *PLoS One* 6 (2011) e17526.
- [68] R. Barrett-Jolley, R. Lewis, R. Fallman, A. Mobasheri, The emerging chondrocyte channelome, *Front. Physiol.* 1 (2010) 135.
- [69] F. Guilak, H.A. Leddy, W. Liedtke, Transient receptor potential vanilloid 4: the sixth sense of the musculoskeletal system? *Ann. N. Y. Acad. Sci.* 1192 (2010) 404–409.
- [70] G. Burnstock, Purinergic mechanosensory transduction and visceral pain, *Mol. Pain* 5 (2009) 69.
- [71] D.M. Salter, M.O. Wright, S.J. Millward-Sadler, NMDA receptor expression and roles in human articular chondrocyte mechanotransduction, *Biorheology* 41 (2004) 273–281.
- [72] R. Zakany, Z. Sziogyarto, C. Matta, T. Juhasz, C. Csontos, K. Szucs, G. Czifra, T. Biro, L. Modis, P. Gergely, Hydrogen peroxide inhibits formation of cartilage in chicken micromass cultures and decreases the activity of calcineurin: implication of ERK1/2 and Sox9 pathways, *Exp. Cell Res.* 305 (2005) 190–199.
- [73] C. Matta, J. Fodor, Z. Sziogyarto, T. Juhasz, P. Gergely, L. Csernoch, R. Zakany, Cytosolic free Ca2+ concentration exhibits a characteristic temporal pattern during in vitro cartilage differentiation: a possible regulatory role of calcineurin in Ca-signalling of chondrogenic cells, *Cell Calcium* 44 (2008) 310–323.



- [74] J. Fodor, C. Matta, T. Juhasz, T. Olah, M. Gonczi, Z. Sziogyarto, P. Gergely, L. Csernoch, R. Zakany, Ionotropic purinergic receptor P2X4 is involved in the regulation of chondrogenesis in chicken micromass cell cultures, *Cell Calcium* 45 (2009) 421–430.
- [75] J. Fodor, C. Matta, T. Olah, T. Juhasz, R. Takacs, A. Toth, B. Dienes, L. Csernoch, R. Zakany, Store-operated calcium entry and calcium influx via voltage-operated calcium channels regulate intracellular calcium oscillations in chondrogenic cells, *Cell Calcium* 54 (2013) 1–16.
- [76] Z. Varga, T. Juhasz, C. Matta, J. Fodor, E. Katona, A. Bartok, T. Olah, A. Sebe, L. Csernoch, G. Panyi, R. Zakany, Switch of voltage-gated K<sup>+</sup> channel expression in the plasma membrane of chondrogenic cells affects cytosolic Ca<sup>2+</sup>-oscillations and cartilage formation, *PLoS One* 6 (2011) e27957.
- [77] C. Matta, R. Zakany, A. Mobasher, Voltage-dependent calcium channels in chondrocytes: roles in health and disease, *Curr. Rheumatol. Rep.* 17 (2015) 43.
- [78] A. Argentaro, H. Sim, S. Kelly, S. Preiss, A. Clayton, D.A. Jans, V.R. Harley, A SOX9 defect of calmodulin-dependent nuclear import in campomelic dysplasia/autosomal sex reversal, *J. Biol. Chem.* 278 (2003) 33839–33847.
- [79] M.M. Knight, S.R. McGlashan, M. Garcia, C.G. Jensen, C.A. Poole, Articular chondrocytes express connexin 43 hemichannels and P2 receptors—a putative mechanoreceptor complex involving the primary cilium? *J. Anat.* 214 (2009) 275–283.
- [80] M. Koolpe, D. Pearson, H.P. Benton, Expression of both P1 and P2 purine receptor genes by human articular chondrocytes and profile of ligand-mediated prostaglandin E2 release, *Arthritis Rheum.* 42 (1999) 258–267.
- [81] G. Burnstock, A. Verkhatsky, Long-term (trophic) purinergic signalling: purinoceptors control cell proliferation, differentiation and death, *Cell Death Dis.* 1 (2010) e9.
- [82] S.M. Richardson, G. Kalamegam, P.N. Pushparaj, C. Matta, A. Memic, A. Khademhosseini, R. Mobasher, F.L. Poletti, J.A. Hoyland, A. Mobasher, Mesenchymal stem cells in regenerative medicine: focus on articular cartilage and intervertebral disc regeneration, *Methods* (2015).
- [83] M.A. Costa, A. Barbosa, E. Neto, A. Sa-e-Sousa, R. Freitas, J.M. Neves, T. Magalhaes-Cardoso, F. Ferreirinha, P. Correia-de-Sa, On the role of subtype selective adenosine receptor agonists during proliferation and osteogenic differentiation of human primary bone marrow stromal cells, *J. Cell. Physiol.* 226 (2011) 1353–1366.
- [84] I. D'Alimonte, E. Nargi, A. Lannutti, M. Marchisio, L. Pierdomenico, G. Costanzo, P.D. Iorio, P. Ballerini, P. Giuliani, F. Ciacigli, R. Ciccarelli, Adenosine A1 receptor stimulation enhances osteogenic differentiation of human dental pulp-derived mesenchymal stem cells via WNT signaling, *Stem Cell Res.* 11 (2013) 611–624.
- [85] S. Koelling, J. Kruegel, M. Irmer, J.R. Path, B. Sadowski, X. Miro, N. Miosge, Migratory chondrogenic progenitor cells from repair tissue during the later stages of human osteoarthritis, *Cell Stem Cell* 4 (2009) 324–335.
- [86] C. Matta, J. Fodor, N. Miosge, R. Takacs, T. Juhasz, H. Rybaltovszki, A. Toth, L. Csernoch, R. Zakany, Purinergic signalling is required for calcium oscillations in migratory chondrogenic progenitor cells, *Pflugers Arch.* 467 (2015) 429–442.
- [87] A.K. Rosenthal, D. Hempel, I.V. Kurup, I. Masuda, L.M. Ryan, Purine receptors modulate chondrocyte extracellular inorganic pyrophosphate production, *Osteoarthritis Cartilage* 18 (2010) 1496–1501.
- [88] S.H. Carroll, K. Ravid, Differentiation of mesenchymal stem cells to osteoblasts and chondrocytes: a focus on adenosine receptors, *Expert Rev. Mol. Med.* 15 (2013) e1.
- [89] Y.S. Lee, C.M. Chuong, Activation of protein kinase A is a pivotal step involved in both BMP-2- and cyclic AMP-induced chondrogenesis, *J. Cell. Physiol.* 170 (1997) 153–165.
- [90] J.B. Noronha-Matos, M.A. Costa, M.T. Magalhaes-Cardoso, F. Ferreirinha, J. Pelletier, R. Freitas, J.M. Neves, J. Sevigny, P. Correia-de-Sa, Role of ecto-NTPDases on UDP-sensitive P2Y(6) receptor activation during osteogenic differentiation of primary bone marrow stromal cells from postmenopausal women, *J. Cell. Physiol.* 227 (2012) 2694–2709.
- [91] N. Zippel, C.A. Limbach, N. Ratajski, C. Urban, C. Luparello, A. Pansky, M.U. Kassack, E. Tobiasch, Purinergic receptors influence the differentiation of human mesenchymal stem cells, *Stem Cells Dev.* 21 (2012) 884–900.
- [92] G. Biver, N. Wang, A. Gartland, I. Orriss, T.R. Arnett, J.M. Boeynaems, B. Robaye, Role of the P2Y13 receptor in the differentiation of bone marrow stromal cells into osteoblasts and adipocytes, *Stem Cells* 31 (2013) 2747–2758.
- [93] K. Roszek, D. Porowinska, A. Bajek, M. Holysz, J. Czarnecka, Chondrogenic differentiation of human mesenchymal stem cells results in substantial changes of ecto-nucleotides metabolism, *J. Cell. Biochem.* 116 (2015) 2915–2923.
- [94] S. Kawano, K. Otsu, A. Kuruma, S. Shoji, E. Yanagida, Y. Muto, F. Yoshikawa, Y. Hirayama, K. Mikoshiba, T. Furuichi, ATP autocrine/paracrine signaling induces calcium oscillations and NFAT activation in human mesenchymal stem cells, *Cell Calcium* 39 (2006) 313–324.
- [95] M.P. Meyer, K. Swann, G. Burnstock, J.D. Clarke, The extracellular ATP receptor, cP2Y(1), inhibits cartilage formation in micromass cultures of chick limb mesenchyme, *Dev. Dyn.* 222 (2001) 494–505.
- [96] S.A. Downie, S.A. Newman, Morphogenetic differences between fore and hind limb precartilaginous mesenchyme: relation to mechanisms of skeletal pattern formation, *Dev. Biol.* 162 (1994) 195–208.
- [97] H.J. Kwon, Extracellular ATP signaling via P2X(4) receptor and cAMP/PKA signaling mediate ATP oscillations essential for prechondrogenic condensation, *J. Endocrinol.* 214 (2012) 337–348.
- [98] H.J. Kwon, ATP oscillations mediate inductive action of FGF and Shh signalling on prechondrogenic condensation, *Cell Biochem. Funct.* 31 (2013) 75–81.
- [99] N. Kumahashi, M. Ochi, H. Kataoka, Y. Uchio, H. Kakimaru, K. Sugawara, K. Enomoto, Involvement of ATP, increase of intracellular calcium and the early expression of c-fos in the repair of rat fetal articular cartilage, *Cell Tissue Res.* 317 (2004) 117–128.